Please login to the form below
asthma drug
This page shows the latest asthma drug news and features for those working in and with pharma, biotech and healthcare.
AZ says dropping MedImmune will help ‘streamline’ its R&D
The Gaithersburg, Maryland-headquartered company is the source of a chunk of AZ’s biologics pipeline, including cancer immunotherapy Imfinzi (durvalumab) and severe asthma drug Fasenra (benralizumab) that were both highlighted
Latest news
-
FDA rejects GSK’s Nucala for COPD
There was bad if not unexpected news for GlaxoSmithKline late Friday, after the FDA refused to extend the indications of its asthma drug Nucala to include chronic obstructive pulmonary disorder (COPD). ... Meanwhile, Nucala isn’t the first drug in the
-
AZ, Amgen’s first-in-class asthma drug gets breakthrough status
AstraZeneca and partner Amgen have picked up a breakthrough designation from the FDA for tezepelumab, a drug that AZ claims could be a “best in disease” therapy for severe asthma. ... for severe asthma in Europe in January but just failed a test in
-
New cancer drugs can’t quite plug the revenue hole at AZ
Overall sales fell 5% to $10.33bn, however, thanks to generic competition taking another chunk out of cholesterol drug Crestor (rosuvastatin) sales, particularly in Europe and Japan. ... Other bright spots for AZ included the continued growth if
-
Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use
News from pharma, biotech and healthcare. Limited NICE approval for AZ’s asthma drug Fasenra. ... However, the UK's cost-effectiveness watchdog says the drug should only be used in limited circumstances for eosinophilic asthma, when usual therapies
-
PMCPA takes AZ to task over asthma drug press release
A complaint filed by GlaxoSmithKline against AstraZeneca about a press release for its severe asthma drug Fasenra, which competes with GSK’s Nucala, has been largely upheld by the industry governing ... The spat comes as Fasenra and Nucala (mepolizumab)
More from news
Approximately 2 fully matching, plus 109 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
Researchers are now trying to identify biomarker-based subgroups and drug combinations to try to improve therapeutic outcomes for patients. ... up innate immune responses, and Cancer Research UK is repurposing an AZ chemokine CCR4 receptor drug (AZD2098)
-
US health reforms
In fact, it’s safe to say most C-suite drug executives would hardly shed a tear upon news of Obamacare’s swift demise. ... To cite just one example, patients with financial need get an 85% discount on the popular asthma drug Advair, and that’s by
-
Building BRICs: pharma's key emerging markets are becoming giants
In April 2013, Novartis was denied patent protection for its cancer drug, Glivec, by the Indian Supreme Court. ... This follows similar patent defeats in India for Pegasys, Roche's hepatitis drug, Merck's asthma treatment, Singulair, Gilead's Viread (HIV)
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Enterprise Therapeutics appoints CEO
He joins the drug discovery firm from Xention Discovery, where he had served as chief scientific officer since co-founding the company in 2002. ... Discovery. Dr Peter Finan, chairman of Enterprise Therapeutics, said: “John's experience in ion channels,
-
Former RBS head takes the reins as GSK chair
the past year, and to develop new products in order to offset the decline of its best-selling asthma drug, Advair, as part of his new remit.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
- Senior / Principal Medical Writer - MedComms - Home Based / Vari...
-
Excellent Remuneration Packages
- Senior Account Director/ Associate Director- Pharma and Life Sci...
-
Competitive salary and benefits
- Senior Account Manager- Pharma and Life Scienes
-
Competitive salary and benefits
-
Account Director, Medical Education
-
Salary TBC
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Experienced / Senior Account Director - Publications - London
-
Up to £80, 000 plus great benefits
-
Senior Medical Writer
-
Salary TBC
- Freelance Medical Writer - Healthcare Advertising - London
-
Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Project Manager - Medical Communications – South Wales
-
Excellent Remuneration Package
-
Senior Medical Writer
-
Competitive salary and benefits
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Account Manager / Senior Account Manager - Healthcare Advertisin...
-
Excellent Remuneration
- Project Manager - Digital Healthcare - London
-
Excellent Remuneration Package
-
Director – Healthcare PR
-
Salary TBC
Subscribe to our email news alerts
- With Spiriva under pressure, Boehringer moves to bolster pipeline
- Genfit claims FDA breakthrough status for liver disease drug
- Mereo’s shareholders back OncoMed takeover
- Lucid Group announces the appointment of new CFO
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- Q&A: Niels Lund
PMHub
OUTiCO
Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...
Latest intelligence
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- How pharma is progressing their commitment in patient engagement...
- Cuttsy+Cuttsy awarded CPD Platinum by the IPA
- Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
- Breaking Bad
- Six behaviours separate the good brand teams from the bad...
Quick links
Infographics
